Cancer BiologybioRxivPreprint
Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemia
C. Bosc, N. Gadaud, A. Bousard…·J.-E. Sarry
This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.
DOI 10.1101/2020.08.17.253856